FDA Approves new Boehringer COPD Drug

The US Food and Drug Administration (FDA) has approved German drugmaker Boehringer Ingelheim's Stiolto Respimat (tiotropium bromide and olodaterol) once-a-day inhalation spray for long-term treatment of chronic obstructive pulmonary disorder (COPD).

Boehringer's new product combines the active ingredients of its top-selling respiratory drug Spiriva with the active ingredient in Striverdi.

The German company said it expects the drug to be approved in Europe within the coming weeks. Affecting 210 million people worldwide, COPD is regarded as a growing world health priority and is predicted to become the third leading cause of death by 2030.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.